Vanguard Global Advisers’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
Vanguard Global Advisers's BEAM Position: Q3 2026 in Review
Vanguard Global Advisers increased its Beam Therapeutics (BEAM) stake by 1.3% in Q3 2026, buying an estimated $14.1K and bringing the position to 38,569 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.
Vanguard Global Advisers first reported a position in BEAM in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.31M in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- Vanguard Global Advisers held 38,569 shares of Beam Therapeutics worth $943K as of Q3 2026.
- Vanguard Global Advisers bought 505 Beam Therapeutics shares in Q3 2026, an estimated $14.1K.
- Beam Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1742 holding.
- Vanguard Global Advisers first reported a position in Beam Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Beam Therapeutics position peaked at $1.31M in Q2 2026.
- 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.